76 related articles for article (PubMed ID: 17047078)
1. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization.
Yagi H; Hashizume H; Horibe T; Yoshinari Y; Hata M; Ohshima A; Ito T; Takigawa M; Shibaki A; Shimizu H; Seo N
Cancer Res; 2006 Oct; 66(20):10136-44. PubMed ID: 17047078
[TBL] [Abstract][Full Text] [Related]
2. The current status and future direction of percutaneous peptide immunization against melanoma.
Seo N; Takigawa M
J Dermatol Sci; 2007 Nov; 48(2):77-85. PubMed ID: 17719748
[TBL] [Abstract][Full Text] [Related]
3. Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization.
Fujiyama T; Oze I; Yagi H; Hashizume H; Matsuo K; Hino R; Kamo R; Imayama S; Hirakawa S; Ito T; Takigawa M; Tokura Y
J Dermatol Sci; 2014 Jul; 75(1):43-8. PubMed ID: 24802712
[TBL] [Abstract][Full Text] [Related]
4. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
6. Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.
Carlsson B; Sadeghi A; Bengtsson M; Wagenius G; Tötterman TH
J Immunother; 2008 Sep; 31(7):633-43. PubMed ID: 18600181
[TBL] [Abstract][Full Text] [Related]
7. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
8. Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes.
Sommerfeldt N; Beckhove P; Ge Y; Schütz F; Choi C; Bucur M; Domschke C; Sohn C; Schneeweis A; Rom J; Pollmann D; Leucht D; Vlodavsky I; Schirrmacher V
Cancer Res; 2006 Aug; 66(15):7716-23. PubMed ID: 16885374
[TBL] [Abstract][Full Text] [Related]
9. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
[TBL] [Abstract][Full Text] [Related]
11. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
12. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11.
Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H
Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861
[TBL] [Abstract][Full Text] [Related]
13. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
14. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739
[TBL] [Abstract][Full Text] [Related]
15. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
Ait-Tahar K; Liggins AP; Collins GP; Campbell A; Barnardo M; Lawrie C; Moir D; Hatton C; Banham AH; Pulford K
Br J Haematol; 2009 Aug; 146(4):396-407. PubMed ID: 19552722
[TBL] [Abstract][Full Text] [Related]
16. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
[TBL] [Abstract][Full Text] [Related]
17. Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein.
Weng X; Lu S; Zhong M; Liang Z; Shen G; Chen J; Wu X
J Leukoc Biol; 2009 Mar; 85(3):574-81. PubMed ID: 19112092
[TBL] [Abstract][Full Text] [Related]
18. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
19. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M
Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178
[TBL] [Abstract][Full Text] [Related]
20. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
